Search
Log in
Join
Experiences with
Alemtuzumab
Posts
Communities
14 public posts
Filter results
Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights & Diagnostic . .
In patients with demonstrated moderate-to-high-disease activity, early initiation of “high-efficacy” DMTs, such as fingolimod, monoclonal antibodies such as natalizumab and
alemtuzumab
and new generation monoclonal anti-CD20 antibodies such as ocrelizumab may help to better control the disease (Merkel
In patients with demonstrated moderate-to-high-disease activity, early initiation of “high-efficacy” DMTs, such as fingolimod, monoclonal antibodies such as natalizumab and
alemtuzumab
and new generation monoclonal anti-CD20 antibodies such as ocrelizumab may help to better control the disease (Merkel
Vaccines FYI
Some MS therapies, including steroids and disease-modifying therapies like Lemtrada (
alemtuzumab
), Tysabri (natalizumab), and Gilenya (fingolimod), are associated with diminished effectiveness of vaccines and a risk of infection as well.
Some MS therapies, including steroids and disease-modifying therapies like Lemtrada (
alemtuzumab
), Tysabri (natalizumab), and Gilenya (fingolimod), are associated with diminished effectiveness of vaccines and a risk of infection as well.
Campath/ Alemtuzumab
Hi Has anyone been treated with the above medication (I have given both names for it). If you have how was it?and did it work for you? I think I am running out of drug options/ combinations now, and platelets remain at 0. This is the doctors next plan but the hospital have only ever treated 3 people
Hi Has anyone been treated with the above medication (I have given both names for it). If you have how was it?and did it work for you? I think I am running out of drug options/ combinations now, and platelets remain at 0. This is the doctors next plan but the hospital have only ever treated 3 people
Want to take advantage of all our features? Just log in!
Log in
or
Join
Looking for other teachers (particularly a couple who have also had campath/Alemtuzumab)
Hi Realise this is very specific but know from here and was also told on G2 (Infusion bay at Addenbrookes - formally PSSU) that there are a couple of other teachers out there whose Behcet's has been tackled with campath. I would love to link up. I've just finished my fourth course of campath yesterday
Hi Realise this is very specific but know from here and was also told on G2 (Infusion bay at Addenbrookes - formally PSSU) that there are a couple of other teachers out there whose Behcet's has been tackled with campath. I would love to link up. I've just finished my fourth course of campath yesterday
Has anyone disgnosed with Churg Strauss Syndrome (EGPA) has experience of taking Alemtuzmab (Campath)
Question from the face book group if anyone can help Just wondering if anybody has had -
Alemtuzumab
Dr David Jayne has put me forwards for it. I have to wait until June, 6 months clear of Rituximab but hopefully I will finally be able to get things under control with this new one...
Question from the face book group if anyone can help Just wondering if anybody has had -
Alemtuzumab
Dr David Jayne has put me forwards for it. I have to wait until June, 6 months clear of Rituximab but hopefully I will finally be able to get things under control with this new one...
Merely an Accounting Problem
Martin Lockwood treated me with a drug then called Campath, (
Alemtuzumab
) at Addenbrooke’s Hospital Cambridge. I was suffering with Wegener’s Granulomatosis. Since then the Vasculitis Clinic at Addenbrooke’s now headed by Dr.
Martin Lockwood treated me with a drug then called Campath, (
Alemtuzumab
) at Addenbrooke’s Hospital Cambridge. I was suffering with Wegener’s Granulomatosis. Since then the Vasculitis Clinic at Addenbrooke’s now headed by Dr.
The convoluted history of Campath and when side effects can be useful
Coles, the first author of two papers describing phase 3 trials of
alemtuzumab
for Multiple Sclerosis.)
Coles, the first author of two papers describing phase 3 trials of
alemtuzumab
for Multiple Sclerosis.)
Lemtrada (Alemtuzumab) for Multiple Sclerosis - and thyroid issues
Lemtrada is another name for
Alemtuzumab
. This is the Wiki article on it: http://en.wikipedia.org/wiki/
Alemtuzumab
Rod Image is taken from Wiki article.
Lemtrada is another name for
Alemtuzumab
. This is the Wiki article on it: http://en.wikipedia.org/wiki/
Alemtuzumab
Rod Image is taken from Wiki article.
Chlorambucil may be a more reasonable choice for elderly CLL patients than fludarabine.
Alemtuzumab
consolidation did not provide benefit over similar regimens without
alemtuzumab
, irrespective of age." Neil
Alemtuzumab
consolidation did not provide benefit over similar regimens without
alemtuzumab
, irrespective of age." Neil
Had Fludarabine? You can only have irradiated blood...for life.
Irradiated blood components should be used after
alemtuzumab
(anti-CD52) therapy. Their use after rituximab (anti-CD20) is not recommended at this time.
Irradiated blood components should be used after
alemtuzumab
(anti-CD52) therapy. Their use after rituximab (anti-CD20) is not recommended at this time.
Doctors should use different therapies when treating older and younger CLL patients
Alemtuzumab
, aka Campath, ,consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.' Article...
Alemtuzumab
, aka Campath, ,consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.' Article...
An update on where and what Vasculitis UK are about at the moment...
VUK also play an active role in the UK Vasculitis Rare Disease Working Group In terms of current research funding, VUK are supporting trials at Addenbrookes Hospital, Cambridge of a new drug for the treatment of vasculitis,
Alemtuzumab
as well as a project at Birmingham Wellcome Trust Clinical Research
VUK also play an active role in the UK Vasculitis Rare Disease Working Group In terms of current research funding, VUK are supporting trials at Addenbrookes Hospital, Cambridge of a new drug for the treatment of vasculitis,
Alemtuzumab
as well as a project at Birmingham Wellcome Trust Clinical Research
Has anyone any experience of taking Campath? (Alemtuzumab)
We have received an email today asking about Campath. This lady is about to start a course of treatment and is obviously very concerned.
We have received an email today asking about Campath. This lady is about to start a course of treatment and is obviously very concerned.
Vasculitis-uk support research at Addenbrookes for a new drug trial for treatment of vasculitis.
Dr David Jayne's team led by Dr Rona Smith at Addenbrookes are undertaking research into an existing drug,
Alemtuzumab
, to see if it proves to be effective in treating ANCA related vasculitis.
Alemtuzumab
, which is one of the new generation of monoclonal antibodies, like Rituximab.
Dr David Jayne's team led by Dr Rona Smith at Addenbrookes are undertaking research into an existing drug,
Alemtuzumab
, to see if it proves to be effective in treating ANCA related vasculitis.
Alemtuzumab
, which is one of the new generation of monoclonal antibodies, like Rituximab.
Filter results
Clear filters
Posted in
All communities
Vasculitis UK
5 results
CLL Support
4 results
Behçet's UK
1 result
View more
Sort by
Most Relevant
Newest
